Abivax positive phase 3 data for colitis drug

Abivax SA (EPA:ABVX) (NASDAQ:ABVX) reported strong results from late-stage trials of its oral ulcerative colitis treatment, obefazimod.

The drug met its main goal in two large Phase 3 studies, showing a clear benefit over placebo in achieving clinical remission after eight weeks of treatment. Nearly half of the trial participants had previously not responded to other advanced therapies.

Abivax said the safety profile was in line with earlier trials, with no new concerns.

Abivax plans to report long-term maintenance data in 2026 and aims to seek U.S. and European approval later that year if results remain positive.

https://www.investing.com/news/stock-market-news/uslisted-abivax-shares-skyrocket-on-positive-phase-3-data-for-colitis-drug-4147105